These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29037225)

  • 1. YAP transcriptionally regulates COX-2 expression and GCCSysm-4 (G-4), a dual YAP/COX-2 inhibitor, overcomes drug resistance in colorectal cancer.
    Li W; Cao Y; Xu J; Wang Y; Li W; Wang Q; Hu Z; Hao Y; Hu L; Sun Y; Xu G; Ao G
    J Exp Clin Cancer Res; 2017 Oct; 36(1):144. PubMed ID: 29037225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells.
    Ahmed M; Hussain AR; Siraj AK; Uddin S; Al-Sanea N; Al-Dayel F; Al-Assiri M; Beg S; Al-Kuraya KS
    Mol Cancer; 2015 Jul; 14():131. PubMed ID: 26159723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer.
    Dong Y; Wang Z; Xie GF; Li C; Zuo WW; Meng G; Xu CP; Li JJ
    Mol Cancer; 2017 Mar; 16(1):71. PubMed ID: 28356150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
    Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
    Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
    Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
    Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of miR-29a facilitates apoptosis of colorectal carcinoma cell SW480 and suppresses its Paclitaxel resistance.
    Yuan LL; Li L; Liu JN; Mei J; Lei CJ
    Eur Rev Med Pharmacol Sci; 2018 Sep; 22(17):5499-5507. PubMed ID: 30229821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells.
    Wang L; Shi S; Guo Z; Zhang X; Han S; Yang A; Wen W; Zhu Q
    PLoS One; 2013; 8(6):e65539. PubMed ID: 23762387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COX-2 Forms Regulatory Loop with YAP to Promote Proliferation and Tumorigenesis of Hepatocellular Carcinoma Cells.
    Xu G; Wang Y; Li W; Cao Y; Xu J; Hu Z; Hao Y; Hu L; Sun Y
    Neoplasia; 2018 Apr; 20(4):324-334. PubMed ID: 29505957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.
    Rahman M; Selvarajan K; Hasan MR; Chan AP; Jin C; Kim J; Chan SK; Le ND; Kim YB; Tai IT
    Neoplasia; 2012 Jul; 14(7):624-33. PubMed ID: 22904679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt/β-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells.
    Konsavage WM; Kyler SL; Rennoll SA; Jin G; Yochum GS
    J Biol Chem; 2012 Apr; 287(15):11730-9. PubMed ID: 22337891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
    Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
    Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verteporfin can Reverse the Paclitaxel Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression.
    Pan W; Wang Q; Zhang Y; Zhang N; Qin J; Li W; Wang J; Wu F; Cao L; Xu G
    Cell Physiol Biochem; 2016; 39(2):481-90. PubMed ID: 27383277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
    Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
    Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.
    Belli V; Matrone N; Napolitano S; Migliardi G; Cottino F; Bertotti A; Trusolino L; Martinelli E; Morgillo F; Ciardiello D; De Falco V; Giunta EF; Bracale U; Ciardiello F; Troiani T
    J Exp Clin Cancer Res; 2019 Jun; 38(1):236. PubMed ID: 31164152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Xu K; Yagüe E
    Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated analysis identifies microRNA-195 as a suppressor of Hippo-YAP pathway in colorectal cancer.
    Sun M; Song H; Wang S; Zhang C; Zheng L; Chen F; Shi D; Chen Y; Yang C; Xiang Z; Liu Q; Wei C; Xiong B
    J Hematol Oncol; 2017 Mar; 10(1):79. PubMed ID: 28356122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional significance of Hippo/YAP signaling for drug resistance in colorectal cancer.
    Song R; Gu D; Zhang L; Zhang X; Yu B; Liu B; Xie J
    Mol Carcinog; 2018 Nov; 57(11):1608-1615. PubMed ID: 30074279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells.
    Liu BS; Xia HW; Zhou S; Liu Q; Tang QL; Bi NX; Zhou JT; Gong QY; Nie YZ; Bi F
    Oncol Rep; 2018 Oct; 40(4):2171-2182. PubMed ID: 30106444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer.
    Chen ZH; Qi JJ; Wu QN; Lu JH; Liu ZX; Wang Y; Hu PS; Li T; Lin JF; Wu XY; Miao L; Zeng ZL; Xie D; Ju HQ; Xu RH; Wang F
    J Exp Clin Cancer Res; 2019 May; 38(1):196. PubMed ID: 31088567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The COX-2 selective inhibitor-independent COX-2 effect on colon carcinoma cells is associated with the Delta1/Notch1 pathway.
    Zhang H; Ye Y; Bai Z; Wang S
    Dig Dis Sci; 2008 Aug; 53(8):2195-203. PubMed ID: 18320325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.